-
1
-
-
0032847425
-
Oral absorption of the HIV protease inhibitors: A current update
-
Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 1999; 39: 211-238.
-
(1999)
Adv. Drug Deliv. Rev.
, vol.39
, pp. 211-238
-
-
Williams, G.C.1
Sinko, P.J.2
-
2
-
-
0032518290
-
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
-
Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
-
(1998)
J. Clin. Invest.
, vol.101
, pp. 289-294
-
-
Kim, R.B.1
Fromm, M.F.2
Wandel, C.3
-
3
-
-
0032906888
-
Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein
-
Kwei GY, Alvaro RF, Chen Q, et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 1999; 27: 581-587.
-
(1999)
Drug Metab. Dispos.
, vol.27
, pp. 581-587
-
-
Kwei, G.Y.1
Alvaro, R.F.2
Chen, Q.3
-
4
-
-
12644278301
-
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
-
Sparreboom A, Asperen JV, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-2035.
-
(1997)
Proc. Natl. Acad. Sci. USA
, vol.94
, pp. 2031-2035
-
-
Sparreboom, A.1
Asperen, J.V.2
Mayer, U.3
-
5
-
-
0033795486
-
Commentary: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs
-
Chiou WL, Chung SM, Wu TC. Commentary: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 2000; 17: 901-903.
-
(2000)
Pharm. Res.
, vol.17
, pp. 901-903
-
-
Chiou, W.L.1
Chung, S.M.2
Wu, T.C.3
-
6
-
-
0034762283
-
Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants
-
Cox DS, Scott KR, Gao H, Raje S, Eddington ND. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants. J Pharm Sci 2001; 90: 1540-1552.
-
(2001)
J. Pharm. Sci.
, vol.90
, pp. 1540-1552
-
-
Cox, D.S.1
Scott, K.R.2
Gao, H.3
Raje, S.4
Eddington, N.D.5
-
7
-
-
0034083195
-
Enaminones - Versatile therapeutic pharmacophores. Further advances
-
Eddington ND, Cox DS, Roberts RR, Stables JP, Powell CB, Scott KR. Enaminones - versatile therapeutic pharmacophores. Further advances. Curr Med Chem 2000; 7: 417-536.
-
(2000)
Curr. Med. Chem.
, vol.7
, pp. 417-536
-
-
Eddington, N.D.1
Cox, D.S.2
Roberts, R.R.3
Stables, J.P.4
Powell, C.B.5
Scott, K.R.6
-
8
-
-
0034880291
-
Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin
-
Cox DS, Scott KR, Gao H, Raje S, Eddington ND. Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin. Eur J Pharm Biopharm 2001; 52: 145-150.
-
(2001)
Eur. J. Pharm. Biopharm.
, vol.52
, pp. 145-150
-
-
Cox, D.S.1
Scott, K.R.2
Gao, H.3
Raje, S.4
Eddington, N.D.5
-
9
-
-
0027182857
-
Synthesis and anticonvulsant activity of enaminones. 2. Further structure-activity correlations
-
Scott KR, Edafiogho IO, Richardson EL, et al. Synthesis and anticonvulsant activity of enaminones. 2. Further structure-activity correlations. J Med Chem 1993; 36: 1947-1955.
-
(1993)
J. Med. Chem.
, vol.36
, pp. 1947-1955
-
-
Scott, K.R.1
Edafiogho, I.O.2
Richardson, E.L.3
-
10
-
-
0026321138
-
Cell cultures as models for drug absorption across the intestinal mucosa
-
Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carr Syst 1991; 8: 305-330.
-
(1991)
Crit. Rev. Ther. Drug Carr. Syst.
, vol.8
, pp. 305-330
-
-
Artursson, P.1
-
11
-
-
0024593744
-
Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability
-
Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96: 736-749.
-
(1989)
Gastroenterology
, vol.96
, pp. 736-749
-
-
Hidalgo, I.J.1
Raub, T.J.2
Borchardt, R.T.3
-
12
-
-
4043069675
-
In vitro and in vivo functional evaluation of the enaminones as a novel series of P-glycoprotein modulators for different therapeutic agents
-
October 26-30, 2003, Salt Lake City, Utah. (abstr)
-
Salama NN, Scott KR, Eddington ND. In vitro and in vivo functional evaluation of the enaminones as a novel series of P-glycoprotein modulators for different therapeutic agents. In 18th Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October 26-30, 2003, Salt Lake City, Utah. 2003; (abstr).
-
(2003)
18th Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists
-
-
Salama, N.N.1
Scott, K.R.2
Eddington, N.D.3
-
13
-
-
1542346470
-
The influence of enaminones on the transport and oral bioavailability of P-gp substrate therapeutic agents
-
Salama NN, Scott KR, Eddington ND. The influence of enaminones on the transport and oral bioavailability of P-gp substrate therapeutic agents. Int J Pharm 2004; 273: 135-147.
-
(2004)
Int. J. Pharm.
, vol.273
, pp. 135-147
-
-
Salama, N.N.1
Scott, K.R.2
Eddington, N.D.3
-
14
-
-
0023268502
-
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
-
Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-191.
-
(1987)
N. Engl. J. Med.
, vol.317
, pp. 185-191
-
-
Fischl, M.A.1
Richman, D.D.2
Grieco, M.H.3
-
15
-
-
0030895312
-
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations
-
Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209.
-
(1997)
Clin. Pharmacokinet.
, vol.32
, pp. 194-209
-
-
Barry, M.1
Gibbons, S.2
Back, D.3
Mulcahy, F.4
-
16
-
-
0037204543
-
Progress in understanding the structure-activity relationships of P-glycoprotein
-
Stouch TR, Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 2002; 54: 315-328.
-
(2002)
Adv. Drug Deliv. Rev.
, vol.54
, pp. 315-328
-
-
Stouch, T.R.1
Gudmundsson, O.2
-
17
-
-
0041402720
-
Efflux ratios cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers
-
Troutman MD, Thakker DR. Efflux ratios cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 2003; 20: 1200-1209.
-
(2003)
Pharm. Res.
, vol.20
, pp. 1200-1209
-
-
Troutman, M.D.1
Thakker, D.R.2
-
18
-
-
0042905800
-
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in intestinal epithelium
-
Troutman MD, Thakker DR. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in intestinal epithelium. Pharm Res 2003; 20: 1210-1223.
-
(2003)
Pharm. Res.
, vol.20
, pp. 1210-1223
-
-
Troutman, M.D.1
Thakker, D.R.2
-
19
-
-
0031941789
-
Taxol transport by human intestinal epithelial Caco-2 cells
-
Walle UK, Walle T. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 1998; 26: 343-346.
-
(1998)
Drug Metab. Dispos.
, vol.26
, pp. 343-346
-
-
Walle, U.K.1
Walle, T.2
-
20
-
-
0037261361
-
Enhanced oral bioavailability of paclitaxel by coadministration of the P-glcoprotein inhibitor KR30031
-
Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glcoprotein inhibitor KR30031. Pharm Res 2003; 20: 24-30.
-
(2003)
Pharm. Res.
, vol.20
, pp. 24-30
-
-
Woo, J.S.1
Lee, C.H.2
Shim, C.K.3
Hwang, S.J.4
-
21
-
-
0032883658
-
Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers
-
Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 1999; 16: 1366-1372.
-
(1999)
Pharm. Res.
, vol.16
, pp. 1366-1372
-
-
Batrakova, E.V.1
Li, S.2
Miller, D.W.3
Kabanov, A.V.4
-
22
-
-
0027524642
-
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
-
Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-4602.
-
(1993)
Cancer Res.
, vol.53
, pp. 4595-4602
-
-
Hyafil, F.1
Vergely, C.2
Du Vignaud, P.3
Grand-Perret, T.4
-
23
-
-
0031962285
-
How does P-glycoprotein recognize its substrates?
-
Seelig A. How does P-glycoprotein recognize its substrates? Int J Clin Pharmacol Ther 1998; 36: 50-54.
-
(1998)
Int. J. Clin. Pharmacol. Ther.
, vol.36
, pp. 50-54
-
-
Seelig, A.1
-
24
-
-
3242804613
-
Multidrug resistance and anticonvulsants: New studies with the enaminones
-
Salama NN, Eddington ND, Payne D, Wilson TL, Scott KR. Multidrug resistance and anticonvulsants: New studies with the enaminones. Curr Med Chem 2004; 11: 763-771.
-
(2004)
Curr. Med. Chem.
, vol.11
, pp. 763-771
-
-
Salama, N.N.1
Eddington, N.D.2
Payne, D.3
Wilson, T.L.4
Scott, K.R.5
-
25
-
-
0343258430
-
6-Deoxyacyclovir: A xanthine oxidase-activated prodrug of acyclovir
-
Krenitsky TA, Hall WW, de Miranda P, Beauchamp LM, Schaeffer HJ, Whiteman PD. 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. Proc Natl Acad Sci USA 1984; 81: 3209-3213.
-
(1984)
Proc. Natl. Acad. Sci. USA
, vol.81
, pp. 3209-3213
-
-
Krenitsky, T.A.1
Hall, W.W.2
de Miranda, P.3
Beauchamp, L.M.4
Schaeffer, H.J.5
Whiteman, P.D.6
-
26
-
-
0032955402
-
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
-
Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-304.
-
(1999)
Clin. Pharmacokinet.
, vol.36
, pp. 289-304
-
-
Barry, M.1
Mulcahy, F.2
Merry, C.3
Gibbons, S.4
Back, D.5
-
27
-
-
0030428226
-
In vitro techniques for studying drug metabolism
-
Guengerich FP. In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 1996; 24: 521-533.
-
(1996)
J. Pharmacokinet. Biopharm.
, vol.24
, pp. 521-533
-
-
Guengerich, F.P.1
-
28
-
-
0034940754
-
The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats
-
Sababi M, Borga O, Hultkvist-Bengtsson U. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur J Pharm Sci 2001; 14: 21-27.
-
(2001)
Eur. J. Pharm. Sci.
, vol.14
, pp. 21-27
-
-
Sababi, M.1
Borga, O.2
Hultkvist-Bengtsson, U.3
-
29
-
-
0343416856
-
Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
-
Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201-214.
-
(1997)
Adv. Drug Deliv. Rev.
, vol.27
, pp. 201-214
-
-
Hebert, M.F.1
-
30
-
-
0032907322
-
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
-
Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmacol Res 1999; 16: 408-414.
-
(1999)
Pharmacol. Res.
, vol.16
, pp. 408-414
-
-
Kim, R.B.1
Wandel, C.2
Leake, B.3
-
31
-
-
0036488144
-
The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddc), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors
-
Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddc), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 2002; 80: 392-404.
-
(2002)
J. Neurochem.
, vol.80
, pp. 392-404
-
-
Gibbs, J.E.1
Thomas, S.A.2
-
32
-
-
0032728058
-
Role of P-glycoprotein in the renal transport of dideoxyriucleoside analog drugs
-
Leung S, Bendayan R. Role of P-glycoprotein in the renal transport of dideoxyriucleoside analog drugs. Can J Physiol Pharmacol 1999; 77: 625-630.
-
(1999)
Can. J. Physiol. Pharmacol.
, vol.77
, pp. 625-630
-
-
Leung, S.1
Bendayan, R.2
-
33
-
-
0028935166
-
Modulators of multidrug resistance. Preclinical studies
-
Ford JM. Modulators of multidrug resistance. Preclinical studies. Hemato Oncol Clin North Am 1995; 9: 337-361.
-
(1995)
Hemato. Oncol. Clin. North Am.
, vol.9
, pp. 337-361
-
-
Ford, J.M.1
|